Identifying proteins targeted by specific enzymes involved in protein degradation
Official title: Developing computational methods to identify of endogenous substrates of E3 ubiquitin ligases and molecular glue degraders
Funded at Drexel University · NIH-10930694 · Data updated 2026-11-12
This study is looking at how certain enzymes help the body decide which proteins to break down, especially in diseases like cancer and autoimmune disorders, to find new ways to improve treatment for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Drexel University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $48,852 |
| NIH project number | 5F30EB034594-02 |
| Project ID | NIH-10930694 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with autoimmune diseases or cancers that may be influenced by E3 ligase activity.
✕Less likely to help
Patients with conditions unrelated to protein degradation or those not affected by E3 ligase dysregulation may not benefit from this research.
What this research studies
This research focuses on understanding how certain enzymes, known as E3 ubiquitin ligases, identify and tag proteins for degradation in the body. By developing computational methods, the project aims to uncover the specific proteins that these ligases target, especially in the context of diseases like cancer and autoimmune disorders. The approach involves analyzing genetic mutations and small molecules that can alter the behavior of these ligases, potentially leading to new therapeutic strategies. Patients may benefit from insights gained about how to manipulate these pathways for better disease management.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for diseases by targeting specific proteins for degradation.
How similar studies have gone: Other research has shown promise in targeting E3 ligases for therapeutic purposes, indicating that this approach has potential for success.
Where this research is happening
-
Drexel University
Philadelphia, United States Active
Researchers
- Principal investigator: Mischley, Victoria — Drexel University
- Study coordinator: Mischley, Victoria
Related research
Other NIH-funded projects on the same topics.
-
UnityPhilly App to Help Reversal of Overdoses in Philadelphia
A citywide smartphone app helps bystanders link with nearby people who can give naloxone during opioid overdoses in Philadelphia.
-
HIV-1 Tat variation and its link to NeuroHIV health
This research looks at how different HIV-1 Tat protein variants may contribute to neurocognitive problems in adults living with HIV.
-
Longitudinal study of Plasmodium vivax relapses in Central Africa
This study follows people in Central Africa to understand how Plasmodium vivax relapses affect illness and transmission.
-
Linking childhood neurodevelopmental disorders with later-life brain diseases
A large international study will look at whether early conditions like autism and ADHD are linked to higher risk of Alzheimer’s, Parkinson’s, or ALS later in life by analyzing health records and genetic data.
-
Linking developmental disorders with later neurodegenerative diseases
A multinational study will look at how early neurodevelopmental conditions like ASD and ADHD relate to risks of later dementia and other neurodegenerative diseases in adults.
-
Predicting Weight Regain After Weight Loss Through Body Signals
A study with people who are losing weight will check how their body’s metabolism and appetite signals might influence if they regain weight later.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.